Trevathan E, Murphy CC, Yeargin-Allsopp M. Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children. Epilepsia. 1997 Dec. 38(12):1283-8. [QxMD MEDLINE Link].
Arzimanoglou A, French J, Blume WT, Cross JH, Ernst JP, Feucht M, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009 Jan. 8(1):82-93. [QxMD MEDLINE Link]. [Full Text].
Engel J Jr; International League Against Epilepsy (ILAE). A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia. 2001 Jun. 42(6):796-803. [QxMD MEDLINE Link].
Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010 Apr. 51 (4):676-85. [QxMD MEDLINE Link].
Heiskala H. Community-based study of Lennox-Gastaut syndrome. Epilepsia. 1997 May. 38(5):526-31. [QxMD MEDLINE Link].
Oguni H, Hayashi K, Osawa M. Long-term prognosis of Lennox-Gastaut syndrome. Epilepsia. 1996. 37 Suppl 3:44-7. [QxMD MEDLINE Link].
Ohtsuka Y, Amano R, Mizukawa M, Ohtahara S. Long-term prognosis of the Lennox-Gastaut syndrome. Jpn J Psychiatry Neurol. 1990 Jun. 44(2):257-64. [QxMD MEDLINE Link].
Bare MA, Glauser TA, Strawsburg RH. Need for electroencephalogram video confirmation of atypical absence seizures in children with Lennox-Gastaut syndrome. J Child Neurol. 1998 Oct. 13(10):498-500. [QxMD MEDLINE Link].
Al-Banji MH, Zahr DK, Jan MM. Lennox-Gastaut syndrome. Management update. Neurosciences (Riyadh). 2015 Jul. 20 (3):207-12. [QxMD MEDLINE Link].
van Rijckevorsel K. Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatr Dis Treat. 2008 Dec. 4(6):1001-19. [QxMD MEDLINE Link]. [Full Text].
Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord. 2007 Dec. 9(4):353-412. [QxMD MEDLINE Link].
Conry JA, Ng YT, Paolicchi JM, Kernitsky L, Mitchell WG, Ritter FJ, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia. 2009 May. 50(5):1158-66. [QxMD MEDLINE Link].
Ng YT, Collins SD. Clobazam. Neurotherapeutics. 2007 Jan. 4(1):138-44. [QxMD MEDLINE Link].
Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011 Oct 11. 77(15):1473-1481. [QxMD MEDLINE Link].
Feucht M, Brantner-Inthaler S. Gamma-vinyl-GABA (vigabatrin) in the therapy of Lennox-Gastaut syndrome: an open study. Epilepsia. 1994 Sep-Oct. 35(5):993-8. [QxMD MEDLINE Link].
You SJ, Kang HC, Kim HD, Lee HS, Ko TS. Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience. Brain Dev. 2008 Apr. 30(4):287-90. [QxMD MEDLINE Link].
Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med. 1997 Dec 18. 337(25):1807-12. [QxMD MEDLINE Link].
Glauser TA. Topiramate. Epilepsia. 1999. 40 Suppl 5:S71-80. [QxMD MEDLINE Link].
Glauser TA, Levisohn PM, Ritter F, Sachdeo RC. Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia. 2000. 41 Suppl 1:S86-90. [QxMD MEDLINE Link].
Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology. 1999 Jun 10. 52(9):1882-7. [QxMD MEDLINE Link].
Pellock JM. Felbamate. Epilepsia. 1999. 40 Suppl 5:S57-62. [QxMD MEDLINE Link].
Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008 May 20. 70(21):1950-8. [QxMD MEDLINE Link].
Kluger G, Kurlemann G, Haberlandt E, Ernst JP, Runge U, Schneider F, et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav. 2009 Mar. 14(3):491-5. [QxMD MEDLINE Link].
Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008 Jul. 49(7):1123-41. [QxMD MEDLINE Link].
Wheless JW, Isojarvi J, Lee D, Drummond R, Benbadis SR. Clobazam is efficacious for patients across the spectrum of disease severity of Lennox-Gastaut syndrome: Post hoc analyses of clinical trial results by baseline seizure-frequency quartiles and VNS experience. Epilepsy Behav. 2014 Oct 2. 41C:47-52. [QxMD MEDLINE Link].
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018 May 17. 378 (20):1888-1897. [QxMD MEDLINE Link].
Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Mar 17. 391 (10125):1085-1096. [QxMD MEDLINE Link].
Ferrie CD, Patel A. Treatment of Lennox-Gastaut Syndrome (LGS). Eur J Paediatr Neurol. 2009 Nov. 13(6):493-504. [QxMD MEDLINE Link].
Lerner JT, Salamon N, Sankar R. Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms. Neuropsychiatr Dis Treat. 2010 Nov 8. 6:731-40. [QxMD MEDLINE Link]. [Full Text].
Ohtsuka Y, Yoshinaga H, Shirasaka Y, Takayama R, Takano H, Iyoda K. Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: A randomized double-blind placebo-controlled trial in Japan. Epilepsy Res. 2014 Nov. 108(9):1627-36. [QxMD MEDLINE Link].
Banzel (rufinamide) [package insert]. Woodcliff Lake, NJ: Eisai Inc. 2/2015. Available at [Full Text].
Lowes R. Clobazam (Onfi) can cause serious skin reactions, FDA warns. Medscape Medical News. December 3, 2013. Available at http://www.medscape.com/viewarticle/815303. Accessed: December 8, 2013.
FDA Drug Safety Communication. FDA warns of serious skin reactions with the anti-seizure drug Onfi (clobazam) and has approved label changes. December 3, 2013. Available at http://www.fda.gov/Drugs/DrugSafety/ucm377204.htm. Accessed: December 8, 2013.
Thiele E, Bebin EM, Bhathal H, et al. Cannabidiol (CBD) treatment in patients with seizures associated with tuberous sclerosis complex: A randomized, double-blind, placebo-controlled phase 3 trial (GWPCARE6) (Abst 1.293). Presented at the American Epilepsy Society 73rd Annual Meeting. 2019 Dec 6-10. Baltimore, MD. [Full Text].
Cukiert A, Burattini JA, Mariani PP, Câmara RB, Seda L, Baldauf CM, et al. Extended, one-stage callosal section for treatment of refractory secondarily generalized epilepsy in patients with Lennox-Gastaut and Lennox-like syndromes. Epilepsia. 2006 Feb. 47(2):371-4. [QxMD MEDLINE Link].
Ben-Menachem E, Hellström K, Waldton C, Augustinsson LE. Evaluation of refractory epilepsy treated with vagus nerve stimulation for up to 5 years. Neurology. 1999 Apr 12. 52(6):1265-7. [QxMD MEDLINE Link].
Lancman G, Virk M, Shao H, Mazumdar M, Greenfield JP, Weinstein S, et al. Vagus nerve stimulation vs. corpus callosotomy in the treatment of Lennox-Gastaut syndrome: a meta-analysis. Seizure. 2013 Jan. 22 (1):3-8. [QxMD MEDLINE Link].
Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008 Jun. 7(6):500-6. [QxMD MEDLINE Link].
Freeman JM, Vining EP, Kossoff EH, Pyzik PL, Ye X, Goodman SN. A blinded, crossover study of the efficacy of the ketogenic diet. Epilepsia. 2009 Feb. 50(2):322-5. [QxMD MEDLINE Link].
De Los Reyes EC, Sharp GB, Williams JP, Hale SE. Levetiracetam in the treatment of Lennox-Gastaut syndrome. Pediatr Neurol. 2004 Apr. 30(4):254-6. [QxMD MEDLINE Link].